NCT02159040View on ClinicalTrials.gov

Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

September 11, 2014

Primary Completion Date

June 26, 2015

Study Completion Date

June 26, 2015

Conditions
High Risk MDS
Interventions
DRUG

Azacitidine

SC or IV AZA at 75mg/m2 7 days/28 day cycle

DRUG

Azacitidine plus Deferasirox

SC or IV AZA at 75mg/m2 7 days/28 day cycle DFX 10mg/kg/day

Trial Locations (6)

14621

Rochester General Hospital / Lipson Cancer Center Lipson Cancer Center, Rochester

21201

University of Maryland Medical Center UM Greenbaum Cancer Ctr (2), Baltimore

38138

The Jones Clinic, Germantown

72205

Hematology Oncology Services of Arkansas HOSA 2, Little Rock

84106

Utah Cancer Specialists IHO Corp, Salt Lake City

91010

City of Hope National Medical Center Oncology, Duarte

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY